Eli Lilly (NYSE:LLY) Q3 results:
Revenue: $5,476.6M (+3.2%).
Net income: $1,253.9M (+9.1%); non-GAAP net income: $1,360.0M (+5.2%); EPS: $1.37 (+22.3%); non-GAAP EPS: $1.48 (+10.4%).
Key product sales: Trulicity: $1,011.5M (+23.9%);
Humalog: $648.9M (-2.4%); Alimta: $508.2M (-2.4%); Forteo: $370.7M
(-5.1%); Taltz: $340.0M (+28.8%); Humulin: $321.8M (flat); Jardiance:
$240.7M (+44.2%); Emgality: $47.7M.
2019 guidance: Revenue: $22.0B – 22.5B (unch); EPS: $8.59 – 8.69 from $8.58 – 8.68; non-GAAP EPS: $5.75 – 5.85 from $5.67 – 5.77.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.